DREAMM-2 Results Move Belantamab Mafodotin Forward in the Treatment of Multiple Myeloma

Results of the phase II DREAMM-2 trial recently published in The Lancet Oncology showed that the investigational agent belantamab mafodotin (GSK2857916) induced response rates above 30% and had a manageable safety profile in patients with heavily pretreated multiple myeloma.

Read the full article here

Related Articles